[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574722":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":16,"locations":24,"responsibleParty":61,"collaborators":63,"id":68,"slug":7,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":7,"enrollmentInfo":76,"targetDuration":79,"studyType":80,"phases":7,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":27,"whyStopped":7,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","OTHER",null,[9,13],{"name":10,"affiliation":11,"role":12},"Serena Di Cosimo, MD, PhD","Fondazione IRCCS Istituto Nazionale dei Tumori di Milano","PRINCIPAL_INVESTIGATOR",{"name":14,"affiliation":11,"role":15},"Paolo Verderio, PhD","STUDY_CHAIR",[17,21],{"name":10,"role":18,"phone":19,"phoneExt":7,"email":20},"CONTACT","+39 02 2390 2700","serena.dicosimo@istitutotumori.mi.it",{"name":14,"role":18,"phone":22,"phoneExt":7,"email":23},"+39 02 2390 3201","paolo.verderio@istitutotumori.mi.it",[25,44],{"facility":26,"status":27,"city":28,"state":7,"zip":29,"country":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Ospedale Di Summa-Perrino","RECRUITING","Brindisi","72100","Italy",{"type":32,"coordinates":33},"Point",[34,35],17.93607,40.63215,{"lat":35,"lon":34},[38,42],{"name":39,"role":18,"phone":40,"phoneExt":7,"email":41},"Saverio Cinieri, MD","+39 0831537217","saverio.cinieri@gmail.com",{"name":43,"role":12,"phone":7,"phoneExt":7,"email":7},"Laura Orlando, MD",{"facility":45,"status":27,"city":46,"state":7,"zip":47,"country":30,"cosmosGeoPoint":48,"geoPoint":52,"contacts":53},"Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale","Naples","80131",{"type":32,"coordinates":49},[50,51],14.26811,40.85216,{"lat":51,"lon":50},[54,59],{"name":55,"role":18,"phone":56,"phoneExt":57,"email":58},"Michelino De Laurentiis, MD","+39 081 7461111","+39 081590369","m.delaurentiis@istitutotumori.na.it",{"name":60,"role":12,"phone":7,"phoneExt":7,"email":7},"Roberta Caputo, MD",{"type":62,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[64,66],{"name":45,"class":65},"NETWORK",{"name":26,"class":67},"UNKNOWN","100574722",false,"NCT06762977","A Composite Assay for HER2-positive Early-stage Breast Cancer Management","HERCard","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Operable breast cancer (stage I-III)\n3. Any status of hormone receptor in the primary tumor, according to institutional guidelines\n4. HER2-positive primary tumor, according to ASCO guidelines, i.e., HER2-positive phenotype by immunohistochemistry (IHC) 3+ or 2+ with a positive result for ERBB2 gene amplification analysis using ISH techniques (CISH, SISH, FISH)\n5. Neoadjuvant and\u002For adjuvant therapy based on trastuzumab ± pertuzumab\n6. Written informed consent from patients\n\nExclusion Criteria:\n\n1. Patient in follow-up for less than 3 years after surgery\n2. A prior diagnosis of invasive cancer before the diagnosis of breast cancer","ALL","18 Years",{"count":77,"type":78},180,"ESTIMATED","3 Years","OBSERVATIONAL","The goal of this observational study is to assess the prognostic value of a genomic classifier (S18) and its refined version (S\\*) in women with early-stage HER2-positive breast cancer. The study aims to determine whether these tools can predict event-free (EFS) and disease-free survival (DFS) in patients treated with neoadjuvant and\u002For adjuvant trastuzumab-based therapies.",[83,84],"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","HER2",[86,87,88,89],"HER2-positive","operable breast cancer","gene-expression based classifier","prognosis","2025-01-07",{"date":92,"type":93},"2025-01-08","ACTUAL",{"date":95,"type":93},"2024-11-13",{"date":97,"type":78},"2026-08",{"name":5,"class":6},2]